Related Experiment Video

Updated: Jul 6, 2025

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

610

Combination Electroacupuncture and Guidelines Directed Medical Therapy Maintained Stability of Heart Rate and Mean

Dwi Surya Supriyana1, Arsita Eka Prasetyawati2, Habibie Arifianto3

  • 1Department of Medical Acupunture, Medical Acupuncture Physician, Faculty of Medicine, Universitas Sebelas Maret, Surakarta/Medical Acupuncture Division, Universitas Sebelas Maret Teaching Hospital, Surakarta, Indonesia.

Medical Acupuncture
|January 1, 2024
PubMed

Insights

Electroacupuncture combined with medications helps stabilize heart rate and mean arterial pressure in patients with chronic heart failure with reduced ejection fraction. This therapy offers a promising approach for managing heart failure risk factors.

Area of Science:

  • Cardiology
  • Integrative Medicine
  • Acupuncture Research

Background:

  • Electroacupuncture (EA) demonstrates therapeutic effects on heart failure (HF) risk factors.
  • Chronic heart failure with reduced ejection fraction (HFrEF) requires effective management strategies.
  • Maintaining stable hemodynamic parameters is crucial for HFrEF patients.

Purpose of the Study:

  • To evaluate the impact of combining drug therapy with EA on heart rate (HR) and mean arterial pressure (MAP) in chronic HFrEF patients.
  • To compare the effects of EA versus sham acupuncture (SA) and no acupuncture in patients receiving standard drug treatment.
  • To assess the efficacy of EA in stabilizing hemodynamic parameters in HFrEF.

Main Methods:

  • A single-blind, randomized controlled trial involving 42 patients with chronic HFrEF.
  • Patients were allocated to three groups: drugs + EA, drugs + SA, or drugs alone.
  • All participants received 16 treatment sessions over 8 weeks.

Main Results:

  • The drugs + EA group showed a significant difference in average MAP over therapy duration.
  • MAP significantly differed in the drugs + EA group from baseline to mid- and end-therapy.
  • No significant differences in mean HR were observed between groups; however, patients receiving drugs + EA exhibited stable MAP and HR post-treatment.

Conclusions:

  • Combination therapy with drugs and EA effectively maintains stable mean arterial pressure and heart rate in patients with chronic HFrEF.
  • EA represents a viable adjunct therapy for hemodynamic stabilization in HFrEF management.
  • This approach may contribute to better risk factor management in heart failure.
Abstract

Keywords:
electroacupunctureheart failureheart ratemean arterial pressurereduced ejection fraction

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

184

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K